HealthDay News — Glycosylated fibronectin may be able to identify first-trimester pregnant women who are at risk for developing gestational diabetes, researchers found.
Above a threshold of 120 mg/L, glycosylated fibronectin levels had a 63% positive predictive value, correctly identifying 57 of 90 pregnant women who developed diabetes at 5 to 13 weeks gestation (95% CI: 53%-72%) and a 95% negative predictive value (95% CI: 94%-95%), Juha P. Rasanen, MD, PhD, of Oregon Health and Science University in Portland, and colleagues reported in Obstetrics & Gynecology.
To evaluate whether certain biomarkers have the potential to identify pregnant women in the first trimester who are at risk for developing gestational diabetes later, the researchers compared serum concentrations of glycosylated fibronectin, adiponectin, sex hormone-binding globulin, placental lactogen and high sensitivity C-reactive protein among 90 pregnant women who developed diabetes at 5 to 13 weeks gestation and 92 control participants.
The researchers observed a significant association between gestational diabetes and first-trimester serum concentrations for all of the potential biomarkers; however, glycosylated fibronectin was the only serum identified that remained independently associated with developing gestational diabetes after the researchers adjusted for maternal factors and other markers (P<.001).
“First-trimester glycosylated fibronectin is a potential pregnancy-specific biomarker for early identification of women at risk for gestational diabetes,” the researchers wrote.
Several authors disclosed financial ties to DiabetOmics, which funded the study.